Search clinical trials for: Tislelizumab combined with Levatinib

Total 1201 results

Sun Yat-sen University

Recruiting

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (TALENT)

Recurrent Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Guangxi Medical University

Completed

HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC (FRONT-1)

Liver Cancer

China
XIANG YANQUN

Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Nasopharyngeal Carcinoma

China
Guangdong Provincial People's Hospital

Recruiting

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Wuhan Union Hospital, China

Recruiting

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Breast Cancer | Neoadjuvant Therapy

China
Fudan University

Recruiting

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Nasopharyngeal Carcinoma

China
Cancer Hospital of Guangxi Medical University

Active, not recruiting

Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma

TACE | Lenvatinib | Tislelizumab | Advanced Unresectable Hepatocellular Carcinoma

China
Ruijin Hospital

Not yet recruiting

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China
Ningbo No. 1 Hospital
Zhejiang University

Recruiting

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Diffuse Large B-cell Lymphoma

China
Fudan University

Recruiting

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Biliary Tract Cancer

China
RenJi Hospital

Recruiting

Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibody

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
First Affiliated Hospital of Guangxi Medical University

Recruiting

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Rectal Cancer | Rectal Cancer Stage II | Rectal Cancer Stage III

China
The First Affiliated Hospital of Xinxiang Medical...
BeiGene

Not yet recruiting

Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

ESCC
Shanghai Zhongshan Hospital

Active, not recruiting

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Left-sided Colorectal Cancer Complicating Acute Obstruction
Guangxi Medical University

Completed

TACE Combined With Donafenib and Tislelizumab in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Immix Biopharma, Inc.
Novartis; BeiGene

Recruiting

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01)

Advanced Solid Tumor

Brazil
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

Gastric Cancer

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

Resectable Hepatocellular Carcinoma
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Colorectal Cancer | Liver Metastases

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Bladder Cancer

China
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China
Renmin Hospital of Wuhan University

Completed

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (RENMIN-213)

Advanced Gastric Adenocarcinoma

China
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Nanfang Hospital, Southern Medical University

Recruiting

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Gastric Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

China
Sun Yat-sen University

Recruiting

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Clear Cell Renal Cell Carcinoma | Neoadjuvant Therapy | Cadonilimab

China
Sun Yat-sen University

Not yet recruiting

Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

China
Sichuan University

Not yet recruiting

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Carrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Objective Response Rate (ORR)
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
Xijing Hospital

Recruiting

Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Fudan University

Not yet recruiting

A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis (Miracle-1)

Advanced Rectal Cancer | Liver Metastasis | Pulmonary Metastasis | Microsatellite Stable Colorectal Carcinoma

China
Hunan Province Tumor Hospital

Recruiting

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Small-cell Lung Cancer

China
Sun Yat-sen University

Recruiting

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

Liver Tumor

China
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)

Muscle Invasive Bladder Cancer

United States, China
Wen Li

Recruiting

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer Stage IV

China
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
Peking Union Medical College Hospital

Recruiting

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Hepatocellular Carcinoma

China
Tianjin Medical University Second Hospital

Recruiting

Tislelizumab Plus Lenvatinib in Stage III-IV RCC (TILUR)

Advanced Kidney Cancer

China
Wen Tianfu

Recruiting

Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

Advanced Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma Non-resectable

China

3

Subscribe